10-K/A: AngioDynamics Files Amended 10-K, Details Executive Compensation

AngioDynamics, Inc. has filed an amended annual report (10-K/A) to include previously omitted Part III information, focusing on corporate governance, executive compensation, and security ownership, while also detailing fiscal year 2026 performance and outlook.

Summary

• AngioDynamics filed an Amendment No. 1 to its Form 10-K for the fiscal year ended May 31, 2026, to include Part III information regarding directors, executive officers, corporate governance, executive compensation, and security ownership.
• The company reported GAAP revenue increased by 9.5% to $320.2 million for fiscal year 2026, with Med Tech and Med Device platforms growing by 18.4% and 2.6% respectively.
• Gross margin improved by 70 basis points to 54.6%, but the net loss widened by $2.7 million to $36.7 million, resulting in a loss per share of $0.88.
• The filing details the compensation structure for Named Executive Officers (NEOs), emphasizing performance-based and at-risk compensation, with 64% of the CEO's target compensation being performance-based in FY2026.
• Key compensation features include robust stock ownership guidelines, a clawback policy, and a mix of base salary, annual cash incentives, and long-term equity awards.
• Several clinical trials and regulatory milestones were achieved or advanced, including patient enrollment in BTK and RECOVER-AV trials, FDA IDE approvals, and a local coverage determination for NanoKnife IRE.
• The company's Board of Directors consists of eight members, with seven identified as independent under Nasdaq listing standards.
• James C. Clemmer, President and CEO, has announced his intention to retire, with a Transition and Retirement Agreement in place.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting a company in transition with revenue growth and strategic investments, though still reporting a net loss. The focus on growth platforms and positive clinical trial updates are encouraging, balanced by the ongoing net loss and macroeconomic challenges.

Positives

• GAAP reported revenue increased by 9.5% to $320.2 million in fiscal year 2026.
• Med Tech platform revenue grew by 18.4% and Med Device platform revenue grew by 2.6%.
• Gross margin increased by 70 basis points to 54.6%.
• Significant progress in strategic transformation into a customer-focused, technology-driven, growth-oriented company.
• Successful enrollment in key clinical trials like AMBITION BTK and RECOVER-AV.
• Received FDA IDE approvals for APEX-Return and PAVE clinical studies.
• Secured FDA 510(k) clearance for a modified AlphaVac F1885 System.
• Finalized a local coverage determination with Palmetto for NanoKnife IRE for prostate and liver cancer, effective July 5, 2026.

Negatives

• Net loss increased by $2.7 million to $36.7 million in fiscal year 2026.
• Loss per share increased by $0.05 to $0.88.
• Global macroeconomic conditions, including inflationary pressures and consumer demand disruptions, continue to impact the business.

Risks

• Global macroeconomic conditions continue to impact the business, including inflationary pressures and disruptions in consumer demand and hospital operating procedures.
• The company operates in an extremely competitive industry.
• Potential for future restatements of financial results that could trigger clawback provisions for executive compensation.
• The company's ability to attract, motivate, engage, and retain senior executive leadership talent is crucial for achieving long-term goals.

Future Outlook

The company believes its strategic research & development and sales & marketing investments in its growth platforms position it well for fiscal year 2027. Key clinical trials are progressing, and regulatory approvals are being sought for various technologies.

Management Comments

• We maintained our focus on disciplined investments in talent and technologies to drive revenue growth for our company in large, fast growing, highly profitable markets.
• In fiscal year 2026, we initiated and executed on strategic research & development and sales & marketing investments in our growth platforms, which drove growth in fiscal year 2026 and we believe positions us well for fiscal year 2027.
• James C. Clemmer has announced his intention to retire on the earlier of November 30, 2026 and appointment of a successor Chief Executive Officer.

Industry Context

StockSavvy.ai notes that AngioDynamics is operating within the competitive medical device sector, characterized by ongoing innovation, regulatory scrutiny, and consolidation trends. The company's strategic focus on high-growth, high-margin markets like peripheral arterial disease and solid tumor ablation aligns with broader industry efforts to develop advanced therapeutic technologies.

Comparison to Industry Standards

• The company's revenue growth of 9.5% in FY2026 is a positive indicator, though specific industry benchmarks for medical device companies of similar size and focus would be needed for a precise comparison.
• The net loss of $36.7 million, while an increase, is common for companies investing heavily in R&D and market expansion within the medical technology sector.
• The executive compensation structure, with a significant portion tied to performance-based and equity awards, aligns with common practices in the industry to incentivize long-term value creation and retention.
• The peer group for compensation benchmarking includes companies like Accuray Incorporated, Alphatec Holdings, Inc., and Boston Scientific Corporation, indicating AngioDynamics positions itself among established players in the medical device space.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The company's revenue growth and strategic investments are aimed at long-term value creation, though the current net loss may be a concern. Executive compensation is tied to performance, aligning management interests with shareholders.
• Employees: Retention agreements are in place for the executive leadership team, indicating a focus on stability during leadership transition. The company's compliance program and code of conduct aim to foster a positive work environment.
• Management: Significant equity-based compensation and performance incentives are designed to motivate and retain key executives. Severance and change-in-control agreements provide financial security under specific circumstances.

Next Steps

• Continue execution of strategic transformation focused on technologies in large, fast-growing, high-margin markets.
• Leverage research and development and clinical pathway expansion.
• Attract and retain top talent.
• Continue to focus on training of sales teams and conduct targeted physician trainings and symposiums.
• Appoint a successor Chief Executive Officer, following the announced retirement of James C. Clemmer.

Key Dates

Recommendation

The company shows positive revenue growth and strategic progress in key areas, supported by clinical advancements. However, the continued net loss and the upcoming CEO transition introduce uncertainty. A 'hold' recommendation reflects a balanced view, awaiting further clarity on profitability and leadership stability before considering a more aggressive stance.

Keywords

AngioDynamics, Form 10-K/A, Executive Compensation, Corporate Governance, Medical Devices, Revenue Growth, Net Loss, Clinical Trials